NEW YORK, June 19 - Genomica said Tuesday it had appointed Michael Savage, formerly CEO of Molecular Simulations, to its board of directors.

Savage will replace Arnold Levine, who is joining Genomica's scientific advisory board.

Savage was CEO of Molecular Simulations for eight years before the company was acquired by Pharmacopeia in 1998.

Genomica of Boulder, Colo., develops and markets software products and services, designed to enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.